SAINTE-FOY, QUEBEC--(MARKET WIRE)--Sep 21, 2007 -- Bioxel Pharma Inc. (CDNX:BIP.V - News), a leading manufacturer and supplier of taxane active pharmaceutical ingredients (APIs), announced today that it has won its largest paclitaxel order from a well-established multinational pharmaceutical company that is presently completing Phase III clinical trials for a paclitaxel based product. The paclitaxel sale was valued at about $800,000. Paclitaxel deliveries under the order will be completed in October 2007, with repeat orders expected from the same client in the coming months.
